Lycorine Derivative Inhibits SARS‐CoV‐2 Replication by Reducing −1 Programmed Ribosomal Frameshifting via Targeting ZAP
MedComm · 2026-04 · 7 (4)
DOI: 10.1002/mco2.70715 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 06.04.2026. Verfasst von Tingfu Du und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biology Chinese Academy of Medical Sciences & Peking Union Medical College Kunming China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The ongoing evolution of SARS‐CoV‐2 and its immune‐evading variants underscores an urgent requirement for broad‐spectrum antiviral drugs. In this study, a series of lycorine derivatives was synthesized. This led to the identification of compound 7 as a promising antiviral candidate. Compound 7 exhibited potent inhibitory activity against SARS‐CoV‐2 and its variants, including Alpha, Beta, Delta, and Omicron, in vitro. The antiviral efficacy of compound 7 was then validated in vivo. Treatment with compound 7 significantly reduced viral loads and alleviated lung pathologies in SARS‐CoV‐2‐infected hamsters. Mechanistically, compound 7 directly targeted the short isoform of the zinc‐finger antiviral protein (ZAP‐S) and bound to specific residues (E111, E115, and F549). This result was confirmed using cellular thermal shift assays, bio‐layer interferometry, and mutagenesis studies. This interaction enhanced the ZAP‐S stability and disrupted –1 programmed ribosomal frameshifting (–1PRF), a critical process for viral polyprotein synthesis. The antiviral activity of compound 7 was ZAP‐S‐dependent, as ZAP‐S knockdown abolished its efficacy while overexpression enhanced it. These results established compound 7 as a novel antiviral candidate that can combat SARS‐CoV‐2 and its variants by targeting ZAP to inhibit –1PRF. This compound, therefore, represents a promising therapeutic strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Medical Biology Chinese Academy of Medical Sciences & Peking Union Medical College Kunming China.
- State Key Laboratory of Respiratory Health and Multimorbidity National Center of Technology Innovation For Animal Model Key Laboratory of Pathogen Infection Prevention and Control (Peking Union Medical College) Ministry…
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation Institute of Materia Medica Chinese Academy of Medical…
- Department of Molecular Biology and Biochemistry Institute of Basic Medical Sciences Medical Primate Research Center Neuroscience Center Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
ORCID-Profile: Tingfu Du, Shuaiyao Lu
Zitieren
APA
Du, T., Liu, R., Zhang, X., Shen, L., Tang, C., Wang, J., Cheng, Y., Yu, W., Yin, B., Lu, S., Pan, X., & Peng, X. (2026). Lycorine Derivative Inhibits SARS‐CoV‐2 Replication by Reducing −1 Programmed Ribosomal Frameshifting via Targeting ZAP. MedComm, 7(4). https://doi.org/10.1002/mco2.70715
Vancouver
Du T, Liu R, Zhang X, Shen L, Tang C, Wang J, et al. Lycorine Derivative Inhibits SARS‐CoV‐2 Replication by Reducing −1 Programmed Ribosomal Frameshifting via Targeting ZAP. MedComm. 2026;7(4). doi:10.1002/mco2.70715
BibTeX
@article{Du2026,
author = {Du, Tingfu and Liu, Ruixue and Zhang, Xintian and Shen, Longying and Tang, Cong and Wang, Junbin and Cheng, Yu and Yu, Wenhai and Yin, Bin and Lu, Shuaiyao and Pan, Xiandao and Peng, Xiaozhong},
title = {Lycorine Derivative Inhibits SARS‐CoV‐2 Replication by Reducing −1 Programmed Ribosomal Frameshifting via Targeting ZAP},
journal = {MedComm},
year = {2026},
volume = {7},
number = {4},
doi = {10.1002/mco2.70715}
}
EUVIMED